INDIA - 2023/12/16: In this photo illustration, the Illumina logo is seen displayed on a mobile ... [+] phone screen. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIllumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company’s acquisition of Fluent Biosciences to expand its single-cell analysis and multiomic ...

SAN DIEGO, July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Cal ...

Loading...Loading...Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.Amid this M&A deal, 10x Genomics, Inc TXG shares are trading lower.William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint.William Blair highlights that cost reduction has beco ...

Core Insights - Illumina, Inc. has acquired Fluent BioSciences to enhance its capabilities in single-cell research, aligning with its multiomics growth strategy [1] - The acquisition was completed on July 9 and was funded with cash on hand, though financial terms were not disclosed [1] Single-Cell Research Capabilities - Fluent BioSciences has developed a unique single-cell technology that simplifies the analysis process, making it more accessible and cost-effective [2] - The latest product, PIPseq V, can detect a wide range of cell types and is scalable, processing from 100 to 1 million cells [2] Integration and Synergy Benefits - The integration of Fluent's technology with Illumina's sequencing and informatics solutions is expected to provide a comprehensive solution for single-cell multiomic analysis [3] - This combined offering aims to accelerate research discoveries and enhance the company's product portfolio for single-cell analysis [3] Market Prospects - The global single-cell analysis market is valued at $4.34 billion in 2023 and is projected to grow at a CAGR of 18.7% from 2024 to 2030 [4] - Growth drivers include applications in disease diagnosis, drug discovery, and precision medicine, along with advancements in technology that improve detection capabilities [4] Illumina's Position in Cell Sequencing - Illumina is focused on strengthening its position in the gene sequencing market with competitive products and developing sample-to-answer solutions for clinical adoption [5] - The company is also expanding its genomic capabilities in India and aims to drive greater adoption of next-generation sequencing (NGS) technology [6][7] Share Performance - Over the past year, Illumina's shares have decreased by 23.4%, while the industry has seen a decline of 7% [8]

Core Insights - The acquisition of Fluent BioSciences by Illumina enhances Illumina's capabilities in single-cell research, a key growth area, and supports its multiomics growth strategy [1][2] - Fluent's single-cell analysis technology simplifies the process by eliminating the need for complex and costly instrumentation, making it more accessible to a wider range of customers [1] - The integration of Fluent's PIPseq™ V technology into Illumina's product portfolio aims to provide comprehensive solutions for single-cell analysis, enabling faster and more economical research [2] Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health through genomic insights [4] - The company serves various markets, including life sciences, oncology, reproductive health, and agriculture, with a commitment to maintaining an open NGS platform and supporting existing single-cell partnerships [2][4] Technology and Product Development - Fluent's PIPseq V technology offers high scalability, capable of processing from 100 cells to 1 million, and excels in detecting cell types often missed by current methods [1] - The acquisition, which closed on July 9, 2024, was funded with cash on hand, indicating a strategic investment in enhancing Illumina's product offerings [2]

Key TakeawaysIllumina said it would take a $1.47 billion goodwill impairment charge related to its spinoff of cancer testing company GRAIL.Illumina also said it would take a $420 million charge for GRAIL's in-process R&D.Illumina's purchase of GRAIL prior to regulatory approval had been steeped in controversy for years. The breakup with GRAIL (GRAL) was costly for Illumina (ILMN). The gene sequencing company wrote in a regulatory filing Thursday that it would take a $1.47 billion goodwill impairment charge ...

Tatsiana Volkava/iStock via Getty Images Investment Overview - Illumina Says Goodbye To GRAIL, & It's Worst Ever Business Decision This week, Illumina (NASDAQ:ILMN), the San Diego, California-based gene sequencing giant, brought an end to a disastrous chapter in its relatively short history by completing the divestiture of GRAIL, the cancer testing business it helped to found. The GRAIL saga has run and run, and ultimately, played a significant role in destroying the value of Illumina stock. As I wrote in a ...

(Photo credit should read CFOTO/Future Publishing via Getty Images)Future Publishing via Getty ImagesOn June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84. On the other ...

Following three years of nonstop regulatory hassles, Illumina (ILMN) finally gave up on GRAIL, leading to the successful completion of its spin-off yesterday. Following the announcement, shares of Illumina rose 1.5% at yesterday’s close and also edged up 0.1% during the after-hour trading session.With the divestment now complete, GRAIL will start trading publicly on Nasdaq from Jun 25 under the ticker symbol "GRAL." Illumina will continue to operate its legacy business independently under the ticker symbol ...

The world of biotech stocks got a new member today. Grail (NASDAQ:GRAL) has successfully completed its spinoff from industry leader Illumina (NASDAQ:ILMN). Previously, Grail had functioned as the company’s cancer-testing unit. However, after regulatory pressure, Illumina, known for its advances in the field of DNA sequencing, opted for the spinoff that would allow Grail to function as its own separate entity. Today, GRAL stock begins trading on the Nasdaq in what could be one of the summer’s hottest market ...